Company intelligence / Profile preview

Jiangxi Qingchun Kangyuan Pharmaceutical

Ownership: Private
Development stage: Other

Overview

Jiangxi Qingchun Kangyuan Pharmaceutical focuses on the research & development, production, and sales of proprietary Chinese medicine preparations and herbal extracts. Its products cover multiple therapeutic areas including digestive health, respiratory health, musculoskeletal conditions, and anti-infectives. The company also operates a B2B e-commerce platform for pharmaceutical supply chain management. In February 2024 it was acquired by Tianjin Lisheng Pharmaceutical Co., Ltd., which now uses it as its manufacturing platform for proprietary Chinese medicines.

Therapeutic areas: RheumatologyGastroenterologyPulmonologyInfectious Diseases
Modalities: Proprietary Chinese medicinesSmall moleculeHerbal extract
Industry: Biotech

Drug pipeline

2 assets

Liuweianxiao

Unknown

1 more asset in the full pipeline.

Beyond the preview

Go deeper on Jiangxi Qingchun Kangyuan Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangxi Qingchun Kangyuan Pharmaceutical.